Cefazolin Coverage in Soft Tissue Infections
Cefazolin provides excellent coverage against methicillin-susceptible Staphylococcus aureus (MSSA), Streptococcus pyogenes (group A strep), other streptococci, and common gram-negative organisms including Escherichia coli and Proteus mirabilis in soft tissue infections.
Primary Organisms Covered
Gram-Positive Bacteria
- Staphylococcus aureus (MSSA only, including beta-lactamase-producing strains) - this is the most susceptible organism to cefazolin 1
- Streptococcus pyogenes (group A streptococci)
- Other streptococci including Streptococcus agalactiae
- Streptococcus pneumoniae
Gram-Negative Bacteria
- Escherichia coli - cefazolin is 4-8 fold more active against E. coli compared to cephalothin 2
- Proteus mirabilis
- Klebsiella species (slightly more active than cephalothin) 2
Critical Coverage Gaps
Cefazolin does NOT cover:
- Methicillin-resistant Staphylococcus aureus (MRSA) - uniformly resistant 1
- Enterococci - many strains are resistant 1
- Pseudomonas aeruginosa - resistant 1
- Indole-positive Proteus species (Proteus vulgaris) - resistant 1
- Enterobacter species - resistant 1
- Serratia species - resistant 1
- Anaerobes - poor to no coverage
Clinical Application by Infection Type
Non-Purulent Soft Tissue Infections
According to IDSA guidelines, cefazolin 0.5-1 g IV every 8 hours is appropriate for mild to moderate non-purulent cellulitis where streptococci and MSSA are the primary pathogens 3.
Pyomyositis
For MSSA-confirmed pyomyositis, cefazolin 1 g IV every 8 hours (adults) or 33 mg/kg/dose every 8 hours (pediatrics) is recommended as definitive therapy 3.
Necrotizing Infections
When Staphylococcus aureus is documented as the causative organism in necrotizing soft tissue infections, cefazolin 1 g every 8 hours IV is appropriate for MSSA strains 3.
Important Caveats
You must add vancomycin or another MRSA-active agent if:
- MRSA is suspected or confirmed
- The patient has risk factors for MRSA (injection drug use, prior MRSA infection, recent hospitalization)
- Purulent infections where MRSA prevalence is high
You must add anaerobic coverage (metronidazole or clindamycin) if:
- Infection involves axilla or perineum 3
- Bite wounds are involved 3
- Necrotizing infection with mixed flora is suspected 3
Dosing Considerations
Standard dosing is 1-2 g IV every 8 hours for most infections 3, 1. For patients with high body weight (>120 kg), doses up to 3 g every 8 hours (9 g/day total) have been shown to be safe and well-tolerated 4. Cefazolin achieves excellent tissue penetration with mean tissue concentrations sufficient for bactericidal activity against susceptible organisms 5.
The drug is particularly advantageous because it produces high, sustained serum levels (peak ~185 mcg/mL after 1 g IV dose) with minimal pain on intramuscular injection compared to other cephalosporins 1, 2.